Effect of somatostatin on the pancreatitis-like biochemical changes due to endoscopic pancreatography: Preliminary report

Tamás, Gyula; Tulassay, Zsolt; Papp, J.; Paksy, András; Korányi, László; Kisfaludy, S; Kollin, E; Steczek, K

doi:10.1016/0026-0495(78)90068-9

Cited by 16 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several substances have been used in an attempt to prevent this complication, mainly through inhibition of pancreatic secretion. Somatostatin has been evaluated in several trials with controversial results 7–15 . It inhibits the pancreatic exocrine secretion by suppression of release of secretin and cholecystokinin.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial

Arvanitidis¹,

Anagnostopoulos²,

Giannopoulos³

et al. 2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Somatostatin has been evaluated in several trials with controversial results. [7][8][9][10][11][12][13][14][15] It inhibits the pancreatic exocrine secretion by suppression of release of secretin and cholecystokinin. Somatostatin also reduces the intrapancreatic duct pressure by inhibiting the motility of the sphincter of Oddi.…”

Section: Introductionmentioning

confidence: 99%

Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial

Arvanitidis¹,

Anagnostopoulos²,

Giannopoulos³

et al. 2004

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Clinically there are case reports and un controlled studies showing some benefits of somatostatin in acute pancreatitis [11,20], and the drug seems to protect the pancreas during endoscopic retrograde pancreaticoduodenography [2,19], Perhaps the present study will not resolve the controversy regarding the effects of so matostatin in acute pancreatitis. Neverthe less, it does suggest that blood flow distribu tion patterns effected by somatostatin may contribute to, rather than relieve, the evolu tion of cardiovascular deterioration.…”

Section: Discussionmentioning

confidence: 58%

Microcirculatory Effects of Somatostatin in Acute Pancreatitis

Schröder¹,

Millard

Nakajima

et al. 1988

Eur Surg Res

View full text Add to dashboard Cite

Somatostatin, a 28-amino-acid inhibitory polypeptide has been advocated for the treatment of upper gastrointestinal bleeding and acute pancreatitis. This study examines the effect of somatostatin in acute hemorrhagic pancreatitis in piglets (n = 12), weighing 8–12 kg. Six animals served as controls, and received only fluid resuscitation (0.9%, NaCl, 20 ml/kg/h). Six animals received somatostatin treatment consisting of a 15 µg/kg bolus i.v. given simultaneously with the induction of pancreatitis, and treatment continued with an intravenous infusion (15 µg/kg/h) for 5 h. Cardiac output, heart rate, blood pressure, arterial pO₂ hematocrit and serum amylase were recorded before and each hour during the experiment. Regional blood flow in the gastrointestinal area was measured using the microsphere method. The microspheres labelled with three different isotopes were administered before the experiment and at 2 and 5 h, respectively. There was a significant decrease in the cardiac output (p < 0.05) and an increase in systemic blood pressure in the somatostatin-treated group (p < 0.025). Pancreatic blood flow decreased by 43 % following somatostatin infusion. The decreases at 2 and 5 h were highly significant (p < 0.005). Blood flow to the mucosal but not muscular region of the stomach was decreased by somatostatin. This study suggests that somatostatin might be harmful in acute pancreatitis due to its adverse effects on pancreatic blood flow and cardiac output. However, somatostatin may be effective in reducing gastrointestinal bleeding. If the drug is used clinically, careful monitoring of the cardiac output is necessary.

show abstract

“…Because ERCP is associated with a high rate of complications, including lawsuits [9] , several pharmacological agents and other interventions have been examined in the prevention of post ERCP pancreatitis. The first such trial was published in 1978 [10] . The preventive measures used can be categorized as sphincter relaxants, protease inhibitors, types of contrast, anti-inflammatory/antioxidant agents, anti-secretory compounds, electrosurgical techniques, and placement of various types of stents.…”

Section: Early Successes and Late Failures In The Prevention Of Post mentioning

confidence: 99%

Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography

Lieb

Draganov

2007

WJG

View full text Add to dashboard Cite

Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). The only way to prevent this complication is to avoid an ERCP all together. Because of the risks involved, a careful consideration should be given to the indication for ERCP and the potential risk/benefit ratio of the test. Once a decision to perform an ERCP is made, the procedure should be carried out with meticulous care by an experienced endoscopist, and with a minimum of pancreatic duct opacification. Several pharmacologic agents have been tested, but to date the most important method of reducing post ERCP pancreatitis is the placement of pancreatic stent. Pancreatic stents should be placed in all patients at high risk of this complication such as those undergoing pancreatic sphincterotomy, pancreatic duct manipulation and intervention, and patients with suspected sphincter of Oddi dysfunction. Pancreatic stents should be also considered in patients requiring precut sphincterotomy to gain biliary access.

show abstract

Effect of somatostatin on the pancreatitis-like biochemical changes due to endoscopic pancreatography: Preliminary report

Cited by 16 publications

References 9 publications

Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial

Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial

Microcirculatory Effects of Somatostatin in Acute Pancreatitis

Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography

Contact Info

Product

Resources

About